TrialEBioMedicine2025

Safety, reactogenicity, and immunogenicity of MTBVAC in infants: a phase 2a randomised, double-blind, dose-defining trial in a TB endemic setting.

Michele Tameris et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.